Grade: Pharmaceutical Grade

Factory Location: Nanjing City，China

Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 3-5kg

Contract Manufacturing: CMO

Packaging Information: 10g/package,100g/package

Delivery Lead Time: 20days

Sample Provided: no

Payment Terms: L/C

Insulin icodec is a long-acting human insulin analogue expressed in Escherichia coli through recombinant DNA technology
and chemically modified.Compared to human insulin in terms ofstructure, it has a threonine at the B30 position ofunmanned insulin and introducesC20 fatty acids as side chains. This side ofthe chain passes throuoh low polvethylene alvcoly- L-alutamic acid (0EG) y- The L-Gluinker is inked to the vsine at oosition B29. This change in molecular structure alows codec insuln to achieve strono and reversible binding with albumin, significantly prolonging its half-life in vivo, reaching an astonishing 196 hours, and can be administered once a week. ln addition, it replaces three amino acids in the human insulin seouence: tvrosine at position A14 is replacedwith alutamic acid Al4E, tyrosine at nosition 816 is renlaced with bistidine (816Hl and phenvlalanine at nosition B25 is renlacecwith histidine (B25H). These substitutions reduce their afinity with insulin receptors, thereby reducing insulin receptor bindingmediated clearance, while also reducing enzyme degradation and increasing molecular stability.